Biosensor Technology outperforms standard weight monitoring in detecting Heart failure events

A congestion index derived from biosensor technology on a scale predicted heart failure events more effectively than weight monitoring alone, offering potential for earlier intervention and reduced hospitalizations.

A study presented at the Technology and Heart Failure Therapeutics annual meeting revealed that a congestion index derived from a scale using biosensor technology outperformed standard weight-based monitoring in predicting heart failure (HF) events. The study, known as SCALE-HF 1, enrolled 329 patients with HF of varying ejection fractions who used a cardiac scale (Bodyport) for daily weight and peripheral impedance measurements, from which the congestion index was derived.

The congestion index, which incorporates several FDA-cleared biomarkers of heart function and fluid status, was found to be more sensitive than standard weight-based monitoring (70% vs. 35%; P < .01), with a lower alert rate (2.58 per patient-year vs. 4.18 per patient-year). This higher sensitivity could enable earlier intervention, potentially reducing serious complications that lead to hospitalization.

Advertisement

Dr. Marat Fudim, a cardiologist and advanced heart failure specialist at Duke University Medical Center, highlighted the benefits of the Bodyport cardiac scale’s noninvasive nature and quick measurements, taking just 20 seconds or less. The scale’s ability to transmit data to a clinical dashboard, a patient app, and a monitoring team enhances its utility in monitoring patients with fluid management conditions.

The study’s findings suggest that the congestion index derived from biosensor technology could lead to workflow efficiencies for care teams, reducing the time spent on responding to false alerts. Moreover, the broad applicability of the congestion index across various HF patient populations indicates its potential to improve quality of life and empower patients in managing their condition.

While further prospective studies are ongoing, the hope is that the Bodyport cardiac scale and congestion index will ultimately reduce HF admissions and improve outcomes for patients with HF.